Open Access Articles- Top Results for Ajanta Pharma

Ajanta Pharma

Ajanta Pharma Limited
Public Company
Traded as
Industry Pharmaceuticals, Drugs & Healthcare
Founded 1973
Headquarters Mumbai, Maharashtra[1], India
Key people
Yogesh Agrawal, Managing Director Rajesh Agrawal, Joint Managing Director
Products Branded Generic Formulations / Medicines
Revenue 11px 12083.4 million (US$Lua error in Module:Math at line 495: attempt to index field 'ParserFunctions' (a nil value). million) (2013–2014)
Number of employees
Subsidiaries Ajanta Pharma (Mauritius) Ltd, Ajanta Pharma USA Inc., Ajanta Pharma Philippines Inc.,[2] Ajanta Pharma UK Ltd
Website Official Website


Ajanta Pharma Limited (APL) (BSE532331 | NSEAJANTPHARM) is an Indian multinational, engaged in development, manufacture and marketing of pharmaceutical formulations worldwide, with its headquarters in Mumbai. It has a robust business of Branded Generics across India and about 30 emerging markets. The company has presence in fast-growing specialty therapeutic segments of Cardiology, Dermatology, Ophthalmology and Pain management apart from serving many other main line therapeutic segments like Anti-malarial, Premium anti-biotic, Anti-allergy etc. With its mission of 'Serving Global Health Care Needs Worldwide', a team of 5000+ Ajantaites with different nationalities ensure providing quality medicines to the patients in different parts of the world. Established in 1973, Ajanta Pharma has rich experience of over 4 decades in pharma industry with impeccable record of quality. The company has always been pioneering in its efforts to service the ailing mankind. It has unique advantage of launching innovative R&D products in the market ahead of competition, many of them being first of its kind.

Domestic Business

In India, APL has presence in the fast-growing specialty therapeutic segments of Cardiology, Dermatology, Ophthalmology and Pain management and has been consistently improving its ranking over the years. Company has been launching many new products for providing patient compliance and convenience, which is enabling it to enjoy superior ranking in its therapeutic segments and leadership in some of the sub-therapeutic segments it operates in. Currently company has a basket of 160+ products, out of which 124 are first-to-market in India. A dedicated team of 2500+ field force spread across the country services the domestic market.

Global Business

Ajanta has built an outstanding brand image in the emerging markets of Asia and Africa and is in the process of establishing its presence in USA, the largest pharmaceutical market globally. Ajanta’s export business consists of a basket of 200+ products, which are customized to suit the requirement of each country to make it a specialty business in each of the markets. Currently company’s products are available in more than 30 countries and in many of the markets company’s products are among the leaders in the segment. Currently company has about 1400 product registrations in emerging markets with equal number being under approval, to ensure continued growth in coming years. APL currently has 2 ANDAs (Abbreviated New Drug Application) approved by US FDA and 23 more ANDAs are awaiting approval. Company plans to file 5-6 ANDAs every year with an objective of strengthening its presence in the US market. As of 2014 only Risperidone is marketed in the United States of America. It has already established a front-end team in USA to take care of sales and marketing of its products in the country. APL also has been granted marketing authorization (MA) for Sildenafil Citrate Tablets 50mg & 100mg in UK, Germany, France, The Netherlands, Denmark, Ireland, Hungary, Portugal and Bulgaria and awaiting the MA in Italy, Greece and Belgium which is expected shortly.

Manufacturing Facilities

Ajanta has four manufacturing facilities located in Aurangabad, which are certified for current Good Manufacturing Practices (cGMP) prescribed by World Health Organization (WHO). Out of 4 facilities, 3 facilities are exclusively for formulation manufacturing and 1 facility is for API for captive consumption. Ajanta’s flagship facility in Paithan has approval of USFDA, UKMHRA, WHO- Geneva (pre qualification), UNICEF and many health authorities from different parts of the world. It also has one formulation manufacturing facility at Mauritius through its wholly owned subsidiary. The company is setting-up two more new manufacturing facilities in Gujarat, one at Dahej and another at Savli, which will be operational in FY’16 and FY’17 respectively.


APL has in-house R&D centre 'Advent' recognized by DSIR, Govt. of India, which has state-of-the-art facilities for product and process development. With a team of over 350 scientists, the research centre has built strong capabilities for developing Generic formulations and process chemistry. Generic formulation development include value added technology platforms such as sustained release, control release, extended release, oral dosage to liquids, ointments and eye drops.

Corporate Social Responsibility

APL recognizes its responsibility as a good corporate citizen and does its small bit in the form of focused activities. It has put the best of its efforts focused on free eye camps being conducted in the rural areas for needy people. Thousands of needy and poor people take the advantage of this facility every year. Ajanta is also conscious about the environment and assists in protecting it at all its facilities with best standards being followed.




  1. ^ "Welcome To Ajanta Pharma". Retrieved 9 February 2011. 
  2. ^ "Ajanta Pharma Limited (532331) Company Profile". Retrieved 9 February 2011. 
  3. ^ name="foo-bar">stock-share-price/ajanta-pharma-ltd/ajanta-pharma/532331/

External links